In a patient with non‑dysplastic Barrett’s esophagus, how often should surveillance upper endoscopy (esophagogastroduodenoscopy) be performed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Surveillance Frequency for Non-Dysplastic Barrett's Esophagus

For patients with non-dysplastic Barrett's esophagus, surveillance endoscopy should be performed every 3-5 years for short segments (<3 cm) and every 2-3 years for long segments (≥3 cm). 1, 2

Surveillance Intervals Based on Segment Length

The frequency of surveillance depends primarily on the length of the Barrett's segment, as longer segments carry higher cancer risk:

  • Short segment (<3 cm): Perform surveillance endoscopy every 3-5 years 1, 2, 3
  • Long segment (≥3 cm): Perform surveillance endoscopy every 2-3 years 1, 2
  • Very long segment (≥10 cm): Refer to a Barrett's expert center for surveillance 4

The American Gastroenterological Association specifically recommends 3-5 year intervals for non-dysplastic Barrett's, acknowledging recent data showing the low risk of malignant progression in this population 1, 3. The British Society of Gastroenterology differentiates by length, recommending 3-5 years for segments <3 cm and 2-3 years for segments ≥3 cm 1. The European Society of Gastrointestinal Endoscopy suggests 5-year intervals for segments 1-3 cm and 3-year intervals for segments 3-10 cm 4.

Essential Biopsy Protocol During Surveillance

When performing surveillance endoscopy, adherence to proper biopsy technique is critical for detecting dysplasia:

  • Obtain 4-quadrant biopsies every 2 cm throughout the Barrett's segment 1, 2, 4
  • Take separate targeted biopsies of any visible mucosal irregularities or lesions first, before random biopsies 1, 2
  • Use high-definition white light endoscopy as the standard of care 1, 4
  • Document the extent using the Prague classification (circumferential and maximal extent) 2, 4
  • Ensure minimum 1-minute inspection time per cm of Barrett's length 4

Studies demonstrate that adherence to recommended biopsy protocols is associated with significantly higher rates of dysplasia and cancer detection 1, 2.

Prerequisites for Surveillance

Surveillance should only be offered to patients who meet specific criteria:

  • Patient must be fit enough to undergo endoscopic therapy or esophagectomy if dysplasia or cancer is detected 1, 5
  • Patient should be on at least daily proton pump inhibitor therapy 2
  • Avoid performing biopsies in the presence of severe erosive esophagitis (Los Angeles grade C or D); optimize acid suppression first and repeat after inflammation resolves 1

When to Consider Stopping Surveillance

Surveillance can be discontinued in certain circumstances:

  • When patient reaches 75 years of age at the time of last surveillance endoscopy 4
  • When patient's life expectancy is less than 5 years 4
  • For patients with irregular Z-line or columnar-lined esophagus <1 cm, no routine biopsies or surveillance are advised 4

Critical Pitfalls to Avoid

Do not perform surveillance more frequently than recommended for non-dysplastic Barrett's, as this increases costs and procedural risks without proven benefit 3. The 3-5 year interval represents a significant change from older recommendations of 2-3 years, reflecting updated understanding of the low annual cancer risk (approximately 0.5% per year) 6, 7.

Do not rely on inadequate biopsy sampling, as this results in significantly lower dysplasia detection rates 2. Many practicing gastroenterologists fail to adhere to the Seattle protocol (4-quadrant biopsies every 2 cm), and adherence appears poorest for patients with extensive Barrett's metaplasia who are at highest risk 1.

Always confirm any dysplasia diagnosis with a second expert gastrointestinal pathologist before altering surveillance intervals, as low-grade dysplasia is frequently overcalled by community pathologists 1, 8, 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Surveillance Frequency for Barrett's Esophagus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

The American journal of gastroenterology, 2016

Research

Endoscopic surveillance in Barrett's esophagus.

Minerva gastroenterologica e dietologica, 2002

Guideline

Management of Barrett's Esophagus with Low-Grade Dysplasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended follow-up schedule for a patient with metaplasia without dysplasia of the esophagus, specifically with Barrett's esophagus?
What is the recommended frequency for Esophagogastroduodenoscopy (EGD) monitoring in patients with Barrett's esophagus?
What is the recommended frequency for Esophagogastroduodenoscopy (EGD) surveillance in patients with Barrett's esophagus, with or without dysplasia?
What is the recommended endoscopic surveillance protocol for patients with Barrett's esophagus according to American Society for Gastrointestinal Endoscopy (ASGE) guidelines?
What are the treatment options for Barrett's esophagus?
In an adult intensive care unit (ICU) patient with low cardiac output and hypotension (systolic blood pressure <90‑100 mmHg), how should norepinephrine be initiated, titrated to achieve a mean arterial pressure (MAP) ≥65 mmHg, and when should a second vasopressor be added?
What is the appropriate initial evaluation and management for a patient presenting with flank pain, possible hematuria, nausea and vomiting suggestive of a kidney stone without signs of infection?
How should I manage a patient with pulmonary embolism who is already in the intensive care unit (ICU)?
Can I start tamsulosin now for a man with a 42‑g prostate and lower urinary tract symptoms even though PSA testing is unavailable, or should I wait for PSA results?
What are the indications, dosing regimen, and monitoring parameters for intravenous calcium gluconate in symptomatic hypocalcemia?
How should Barrett's esophagus be managed, including treatment for non‑dysplastic disease and for low‑grade or high‑grade dysplasia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.